| Title |
Clinical Pharmacogenetics Implementation Consortium Guidelines for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing
|
|---|---|
| Published in |
Clinical Pharmacology & Therapeutics, August 2013
|
| DOI | 10.1038/clpt.2013.172 |
| Pubmed ID | |
| Authors |
K E Caudle, C F Thorn, T E Klein, J J Swen, H L McLeod, R B Diasio, M Schwab |
| Abstract |
The fluoropyrimidines are the mainstay chemotherapeutic agents for the treatment of many types of cancers. Detoxifying metabolism of fluoropyrimidines requires dihydropyrimidine dehydrogenase (DPD, encoded by the DPYD gene), and reduced or absent activity of this enzyme can result in severe, and sometimes fatal, toxicity. We summarize evidence from the published literature supporting this association and provide dosing recommendations for fluoropyrimidines based on DPYD genotype (updates at http://www.pharmgkb.org). |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | 50% |
| Unknown | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Scientists | 1 | 50% |
| Members of the public | 1 | 50% |
Mendeley readers
The data shown below were compiled from readership statistics for 273 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| France | 2 | <1% |
| United States | 1 | <1% |
| Spain | 1 | <1% |
| Unknown | 269 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 39 | 14% |
| Student > Master | 38 | 14% |
| Student > Ph. D. Student | 31 | 11% |
| Other | 30 | 11% |
| Student > Doctoral Student | 21 | 8% |
| Other | 71 | 26% |
| Unknown | 43 | 16% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 88 | 32% |
| Biochemistry, Genetics and Molecular Biology | 40 | 15% |
| Agricultural and Biological Sciences | 35 | 13% |
| Pharmacology, Toxicology and Pharmaceutical Science | 33 | 12% |
| Nursing and Health Professions | 5 | 2% |
| Other | 17 | 6% |
| Unknown | 55 | 20% |
Attention Score in Context
This research output has an Altmetric Attention Score of 32. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 10 June 2023.
All research outputs
#1,130,158
of 23,981,346 outputs
Outputs from Clinical Pharmacology & Therapeutics
#143
of 4,302 outputs
Outputs of similar age
#10,108
of 203,628 outputs
Outputs of similar age from Clinical Pharmacology & Therapeutics
#3
of 40 outputs
Altmetric has tracked 23,981,346 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 95th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 4,302 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.4. This one has done particularly well, scoring higher than 96% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 203,628 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 95% of its contemporaries.
We're also able to compare this research output to 40 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 95% of its contemporaries.